Immorna develops mRNA-based therapeutics. The company announced it has raised $100 million in extended Series A rounds. The financings were described as Series A+ and A++ rounds. Proceeds are intended to support the clinical development of its drug candidates. The announcement was made on Monday. No operational metrics or investor names were included in the article.

Total raised

$100M

Funding rounds

1

Latest round

Series A

Latest activity

Feb 2023